Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
from Neurology : nature.com subject feeds https://ift.tt/uLkwY8W
In this podcast, Dr Heidi Moawad interviews a neurologist currently researching new, available treatments in headache medicine. from Front page feed http://bit.ly/2HVwnPv
Comments
Post a Comment